Factor XI and contact activation as targets for antithrombotic therapy.

@article{Gailani2015FactorXA,
  title={Factor XI and contact activation as targets for antithrombotic therapy.},
  author={David Gailani and Charles E. Bane and Andr{\'a}s Gruber},
  journal={Journal of thrombosis and haemostasis : JTH},
  year={2015},
  volume={13 8},
  pages={
          1383-95
        }
}
The most commonly used anticoagulants produce therapeutic antithrombotic effects either by inhibiting thrombin or factor Xa (FXa) or by lowering the plasma levels of the precursors of these key enzymes, prothrombin and FX. These drugs do not distinguish between thrombin generation contributing to thrombosis from thrombin generation required for hemostasis. Thus, anticoagulants increase bleeding risk, and many patients who would benefit from therapy go untreated because of comorbidities that… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

Inhibition of Factor XIa Reduces the Frequency of Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits.

  • The Journal of pharmacology and experimental therapeutics
  • 2017
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Factor XI and factor XII as targets for new anticoagulants.

  • Thrombosis research
  • 2016
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Factor XI as a Therapeutic Target.

  • Arteriosclerosis, thrombosis, and vascular biology
  • 2016
VIEW 10 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Neonatal ECMO

VIEW 1 EXCERPT
CITES BACKGROUND